載入中
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
前收盤價
US$9.04
US$0.00 · 0.00%
盤中時間採用ET。市場資料可能有所延遲。
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
日內區間
目前US$9.04
52週區間
目前US$9.04
盤中時間採用ET。市場資料可能有所延遲。
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
日內區間
目前US$9.04
52週區間
目前US$9.04
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1022.03萬 USD | — | — | — | — |
| 銷貨成本 | 191.53萬 USD | — | — | — | — |
| 毛利 | 830.5萬 USD | — | — | — | — |
| 研究與開發 | 186.8萬 USD | 391.85萬 USD | 499.83萬 USD | 1184.67萬 USD | 1016.19萬 USD |
| 銷售、一般及管理費用 | 2907.61萬 USD | 732.1萬 USD | 468.93萬 USD | 543.91萬 USD | 431.19萬 USD |
| 營業費用 | 3096.56萬 USD | 1186.07萬 USD | 961.78萬 USD | 1809.3萬 USD | 1474.42萬 USD |
| 利息收入 | 189.94萬 USD | 16.17萬 USD | 6804 USD | 2586 USD | 2643 USD |
| 利息支出 | — | 18.58萬 USD | 6.77萬 USD | 23.23萬 USD | 67.31萬 USD |
| 折舊和攤銷 | 5.86萬 USD | 8.12萬 USD | 8.45萬 USD | 12.22萬 USD | 11.45萬 USD |
| 營業利益 | −2266.07萬 USD | −1186.07萬 USD | −961.78萬 USD | −1809.3萬 USD | −1474.42萬 USD |
| 淨利 | −2066.99萬 USD | −1463.69萬 USD | −1377.26萬 USD | −1627.78萬 USD | −2490.98萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.25
上漲空間 90.82%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年11月5日 | 1:25 | — | — |
已生效 2024年11月5日
1:25
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
